Sunshine BioPharma Stock News and Forecast: SBFM rally keeps going on breakthrough cancer treatment


  • SBFM stock soared 148% on Tuesday on positive cancer mRNA news.
  • Sunshine BioPharma shares then added another 12% on Wednesday to close at $6.29.
  • The pharma company stock was up again in Thursday's premarket to $5.49.

Update: Sunshine BioPharma keeps capitalizing on a breakthrough treatment for breast and ovarian cancer. The pharma company announced earlier in the week that it had discovered a successful mRNA treatment for these illnesses, which has helped SBFM skyrocket. Within the first hour of Thursday's Wall Street trading, the Canadian pharmaceutical shares are up another 27% at the time of writing, right at the $8 mark, having set an $8.18 high in the past minutes. This makes it a 235% rise in the past two days since the announcement. Technical analysis is helpless within this kind of volatility, so momentum trading is what matters now for SBFM stock. 

Sunshine BioPharma has been one of the standout performers of the week with a staggering gain on Tuesday. SBFM stock immediately made it to the top of the charts on various social media stock chats and managed to hold those gains on Wednesday.

Read more stock market research

Sunshine Biopharma is a biotech company that is focused on developing and bringing to market antiviral and oncology drugs. Sunshine Bioharma is a small or even micro-cap company with a market cap of just over $40 million. It was only listed in February on the Nasdaq. The company is based in Montreal, Canada and also has partnered with the University of Arizona for an anti coronavirus drug development.

Sunshine Biopharma stock news: Anti-cancer discovery a multi-billion market opportunity

SBFM stock soared due to the company announcing that its mRNA treatment for cancer was effective. Two mRNA molecules were able to treat cancer which was grown in culture. The cancer cells were breast cancer and ovarian. Toxicity studies ie effects on humans were also positive and the company says it hopes to file a patent for the treatments soon.

The mRNA system is now widely known due to most covid vaccines using this technology. The mRNA vaccines work by introducing a piece of a viral protein into the human body. Human cells then produce this viral protein which induces an immune response and the body now produced antibodies to fight the virus. Once the human antibodies have destroyed the virus they are ready to deploy again if the virus is reintroduced to the body. That is the layman's version as I certainly am no scientist!

Sunshine BioPharam said the potential of this discovery is a multi-billion global market opportunity. Pharma investments are usually high risk and depend on trial results and patents, but Moderna (MRNA) is the most obvious example of the huge potential should a company or stock hit a home run.

Sunshine Biopharma (SBFM) stock forecast: Big spike to be followed by reversal?

For now, this certainly looks like very positive news for SFBM stock but it is a long road to bring a drug to commercialization. So we would always urge caution. SBFM shares have spiked on the enthusiasm and the momentum generated. This will begin to stall once newsflow dries up and momentum dies down in SBFM stock.

SBFM will then likely wait until the next data or patent news before reacting again. We can already see this in previous pharma stocks and indeed in SBFM itself. The chart below shows spikes followed by reversals before spiking again on more positive news. 

If SBFM stock follows a similar pattern you would expect it to stabilize somewhere around $4.

SBFM stock chart, daily

 

Share: Feed news

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.

If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.

FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.

The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.

Recommended content


Recommended content

Editors’ Picks

EUR/USD stays pressured below 1.0600, ECB/ Fedspeak eyed

EUR/USD stays pressured below 1.0600, ECB/ Fedspeak eyed

EUR/USD remains depressed below 1.0600 in European trading on Wednesday. The US Dollar advances, tracking US Treasury bond yields higher even though risk appetite returns on fading Russia-Ukraine geopolitical tensions. Central banks' speeches are eyed for fresh impetus.  

EUR/USD News
GBP/USD holds gains near 1.2700 after UK inflation data

GBP/USD holds gains near 1.2700 after UK inflation data

GBP/USD holds the latest uptick near 1.2700 in the European session on Wednesday. The data from the UK showed that the annual inflation, as measured by the change in the CPI, rose to 2.3% in October from 1.7% in September, supporting Pound Sterling.

GBP/USD News
Gold price moves away from one-week top on rising US bond yields, modest USD strength

Gold price moves away from one-week top on rising US bond yields, modest USD strength

Gold price retreats after touching a one-and-half-week top earlier this Wednesday and drops to a fresh daily low, below the $2,630 level heading into the European session. A goodish pickup in the US Treasury bond yields, bolstered by bets for a less aggressive policy easing by the Fed, revives the USD demand and undermines demand for the non-yielding yellow metal. 

Gold News
Why is Bitcoin performing better than Ethereum? ETH lags as BTC smashes new all-time high records

Why is Bitcoin performing better than Ethereum? ETH lags as BTC smashes new all-time high records

Bitcoin has outperformed Ethereum in the past two years, setting new highs while the top altcoin struggles to catch up with speed. Several experts exclusively revealed to FXStreet that Ethereum needs global recognition, a stronger narrative and increased on-chain activity for the tide to shift in its favor.

Read more
How could Trump’s Treasury Secretary selection influence Bitcoin?

How could Trump’s Treasury Secretary selection influence Bitcoin?

Bitcoin remained upbeat above $91,000 on Tuesday, with Trump’s cabinet appointments in focus and after MicroStrategy purchases being more tokens. 

Read more
Best Forex Brokers with Low Spreads

Best Forex Brokers with Low Spreads

VERIFIED Low spreads are crucial for reducing trading costs. Explore top Forex brokers offering competitive spreads and high leverage. Compare options for EUR/USD, GBP/USD, USD/JPY, and Gold.

Read More

Forex MAJORS

Cryptocurrencies

Signatures